Effect of age of transfused red blood cells on neurologic outcome following traumatic brain injury (ABLE-tbi Study): a nested study of the Age of Blood Evaluation (ABLE) trial.

Effet de l’âge des culots sanguins transfusés sur le devenir neurologique après un traumatisme cérébral (étude ABLE-tbi) : une étude imbriquée dans l’essai clinique ABLE (Age of Blood Evaluation).

Journal

Canadian journal of anaesthesia = Journal canadien d'anesthesie
ISSN: 1496-8975
Titre abrégé: Can J Anaesth
Pays: United States
ID NLM: 8701709

Informations de publication

Date de publication:
06 2019
Historique:
received: 17 07 2018
accepted: 10 01 2019
revised: 06 01 2019
pubmed: 28 2 2019
medline: 2 10 2020
entrez: 28 2 2019
Statut: ppublish

Résumé

Anemia is common in critically ill patients with traumatic brain injury, and often requires red blood cell transfusion. Studies suggest that prolonged storage causes lesions of the red blood cells, including a decreased ability to carry oxygen. Considering the susceptibility of the brain to hypoxemia, victims of traumatic brain injury may thus be more vulnerable to exposure to older red blood cells. Our study aimed to ascertain whether the administration of fresh red blood cells (seven days or less) results in a better neurologic outcome compared with standard red blood cells in critically ill patients with traumatic brain injury requiring transfusion. The Age of Blood Evaluation in traumatic brain injury (ABLE-tbi) study was a nested study within the ABLE study (ISRCTN44878718). Our primary outcome was the extended Glasgow Outcome Scale (GOSe) at six months. In the ABLE study, 217 subjects suffered a traumatic brain injury: 110 in the fresh group, and 107 in the standard group. In the fresh group, 68 (73.1%) of the patients had an unfavourable neurologic outcome (GOSe ≤ 4) compared with 60 (64.5%) in the standard group (P = 0.21). Using a sliding dichotomy approach, we observed no overall effect of fresh red blood cells on neurologic outcome (odds ratio [OR], 1.34; 95% confidence interval [CI], 0.72 to 2.50; P = 0.35) but observed differences across prognostic bands with a decreased odds of unfavourable outcome in patients with the best prognosis at baseline (OR, 0.33; 95% CI, 0.11 to 0.96; P = 0.04) but an increased odds in those with intermediate and worst baseline prognosis (OR, 5.88; 95% CI,1.66 to 20.81; P = 0.006; and OR, 1.67; 95% CI, 0.53 to 5.30; P = 0.38, respectively). Overall, transfusion of fresh red blood cells was not associated with a better neurologic outcome at six months in critically ill patients with traumatic brain injury. Nevertheless, we cannot exclude a differential effect according to the patient baseline prognosis. ABLE study (ISRCTN44878718); registered 22 August, 2008.

Sections du résumé

BACKGROUND
Anemia is common in critically ill patients with traumatic brain injury, and often requires red blood cell transfusion. Studies suggest that prolonged storage causes lesions of the red blood cells, including a decreased ability to carry oxygen. Considering the susceptibility of the brain to hypoxemia, victims of traumatic brain injury may thus be more vulnerable to exposure to older red blood cells.
METHODS
Our study aimed to ascertain whether the administration of fresh red blood cells (seven days or less) results in a better neurologic outcome compared with standard red blood cells in critically ill patients with traumatic brain injury requiring transfusion. The Age of Blood Evaluation in traumatic brain injury (ABLE-tbi) study was a nested study within the ABLE study (ISRCTN44878718). Our primary outcome was the extended Glasgow Outcome Scale (GOSe) at six months.
RESULTS
In the ABLE study, 217 subjects suffered a traumatic brain injury: 110 in the fresh group, and 107 in the standard group. In the fresh group, 68 (73.1%) of the patients had an unfavourable neurologic outcome (GOSe ≤ 4) compared with 60 (64.5%) in the standard group (P = 0.21). Using a sliding dichotomy approach, we observed no overall effect of fresh red blood cells on neurologic outcome (odds ratio [OR], 1.34; 95% confidence interval [CI], 0.72 to 2.50; P = 0.35) but observed differences across prognostic bands with a decreased odds of unfavourable outcome in patients with the best prognosis at baseline (OR, 0.33; 95% CI, 0.11 to 0.96; P = 0.04) but an increased odds in those with intermediate and worst baseline prognosis (OR, 5.88; 95% CI,1.66 to 20.81; P = 0.006; and OR, 1.67; 95% CI, 0.53 to 5.30; P = 0.38, respectively).
CONCLUSION
Overall, transfusion of fresh red blood cells was not associated with a better neurologic outcome at six months in critically ill patients with traumatic brain injury. Nevertheless, we cannot exclude a differential effect according to the patient baseline prognosis.
TRIAL REGISTRATION
ABLE study (ISRCTN44878718); registered 22 August, 2008.

Identifiants

pubmed: 30809776
doi: 10.1007/s12630-019-01326-7
pii: 10.1007/s12630-019-01326-7
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

696-705

Subventions

Organisme : Department of Health
ID : 09/144/51
Pays : United Kingdom

Auteurs

Jessica Ruel-Laliberté (J)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada.

Paule Lessard Bonaventure (P)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada.

Dean Fergusson (D)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Jacques Lacroix (J)

CHU Ste-Justine Research Centre, CHU Ste-Justine, Université de Montréal, Montréal, QC, Canada.

Ryan Zarychanski (R)

Department of Internal Medicine, Sections of Critical Care Medicine, of Haematology and of Medical Oncology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada.

François Lauzier (F)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada.
Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.
Department of Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.

Alan Tinmouth (A)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Paul C Hébert (PC)

Department of Medicine, Centre Hospitalier Universitaire de Montréal, Université de Montréal, Montréal, QC, Canada.

Robert Green (R)

Department of Emergency Medicine, Division of Critical Care Medicine, Dalhousie University, Halifax, NS, Canada.

Donald Griesdale (D)

Department of Anesthesiology, Division of Critical Care Medicine, University of British Columbia, Vancouver, BC, Canada.

Robert Fowler (R)

Department of Critical Care Medicine, Sunnybrook Health Services Centre, University of Toronto, Toronto, ON, Canada.

Andreas Kramer (A)

Department of Critical Care Medicine, Foothills Health Sciences Centre, University of Calgary, Calgary, AB, Canada.

Lauralyn A McIntyre (LA)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Department of Critical Care Medicine, The Ottawa Hospital, Ottawa, Ontario, ON, Canada.

David Zygun (D)

Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada.

Tim Walsh (T)

University of Edinburgh, Edinburgh, UK.

Simon Stanworth (S)

Department of Hematology, University of Oxford, Oxford, UK.

Gilles Capellier (G)

Department of Anesthesiology and Critical Care Medicine, Université de Besançon, Besançon, France.

Sébastien Pili-Floury (S)

Department of Anesthesiology and Critical Care Medicine, Université de Besançon, Besançon, France.

Emmanuel Samain (E)

Department of Anesthesiology and Critical Care Medicine, Université de Besançon, Besançon, France.

Lucy Clayton (L)

CHU Ste-Justine Research Centre, CHU Ste-Justine, Université de Montréal, Montréal, QC, Canada.

John Marshall (J)

Department of Medicine, Centre Hospitalier Universitaire de Montréal, Université de Montréal, Montréal, QC, Canada.

Giuseppe Pagliarello (G)

Department of Critical Care Medicine, The Ottawa Hospital, Ottawa, Ontario, ON, Canada.

Elham Sabri (E)

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Xavier Neveu (X)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada.

Caroline Léger (C)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada.

Alexis F Turgeon (AF)

CHU de Québec - Université Laval Research Centre, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Université Laval, Quebec City, QC, Canada. alexis.turgeon@fmed.ulaval.ca.
Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada. alexis.turgeon@fmed.ulaval.ca.
Centre de recherche du CHU de Québec - Université Laval, Population Health and Optimal Health Practices Research Unit, Trauma - Emergency - Critical Care Medicine, Hôpital de l'Enfant-Jésus, 1401, 18e Rue, Room Z-204, Quebec City, QC, G1J 1Z4, Canada. alexis.turgeon@fmed.ulaval.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH